MARKET

OMER

OMER

Omeros
NASDAQ
3.470
+0.150
+4.52%
After Hours: 3.470 0 0.00% 16:02 09/28 EDT
OPEN
3.350
PREV CLOSE
3.320
HIGH
3.580
LOW
3.310
VOLUME
444.09K
TURNOVER
0
52 WEEK HIGH
14.61
52 WEEK LOW
1.855
MARKET CAP
217.67M
P/E (TTM)
-1.1584
1D
5D
1M
3M
1Y
5Y
OMER, GLBE and QURE are among after hour movers
Gainers: Global-E Online  (GLBE) +4%. NETGEAR (<a href="https://seekingal...
Seekingalpha · 2d ago
Why ZW Data Action Technologies Jumped 37%; Here Are 71 Biggest Movers From Yesterday
Gainers
Benzinga · 09/16 08:38
Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary
Benzinga · 09/15 22:47
Analyzing Omeros's Short Interest
Omeros&#39;s (NASDAQ:OMER) short percent of float has fallen 3.78% since its last report. The company recently reported that it has 9.96 million shares sold short, which is 16.54% of all regular shares that are available for trading.
Benzinga · 09/15 19:13
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Benzinga · 09/15 17:40
Why Adobe Is Trading Lower By 17%, Here Are 49 Stocks Moving In Thursday's Mid-Day Session
Gainers HeartBeam, Inc. (NASDAQ: BEAT) shares surged 58% to $1.96 after the company announced its patent for a 12-lead electrocardiogram patch monitor intended for detection of acute coronary syndrome and cardiac arrhythmia was issued by the USPTO.
Benzinga · 09/15 17:03
Omeros COVID-19 Treatment Reduced Mortality Risk, But Biased Data Rendered Analysis Meaningless
Benzinga · 09/15 14:51
US Stocks Gain Following Economic Data; Dow Jumps Over 100 Points
U.S. stocks traded higher this morning, following the release of several economic reports.
Benzinga · 09/15 14:14
More
About OMER
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic diseases, including complement-mediated diseases and cancers related to dysfunction of the immune system, as well as addictive and compulsive disorders. Its lead lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome, and COVID-19. OMS906, its inhibitor of MASP-3, an activator of the alternative pathway of complement, is initiating a Phase I b clinical program in paroxysmal nocturnal hemoglobinuria (PNH).

Webull offers kinds of Omeros Corporation stock information, including NASDAQ:OMER real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OMER stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OMER stock methods without spending real money on the virtual paper trading platform.